Why Is Chemed (CHE) Up 4.5% Since Last Earnings Report?

Core Viewpoint - Chemed's shares have increased by approximately 4.5% since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this positive trend leading up to the next earnings release [1] Company Performance - Chemed has not seen any earnings estimate revisions from analysts in the past two months, indicating a period of stability in expectations [2] - The company holds a VGM Score of B, with a strong Growth Score of A, a Momentum Score of B, but a lower Value Score of D, placing it in the bottom 40% for value investment strategy [3] Outlook - Chemed has a Zacks Rank of 4 (Sell), suggesting expectations of below-average returns in the upcoming months [4] Industry Comparison - Chemed operates within the Zacks Medical - Outpatient and Home Healthcare industry, where DaVita HealthCare has seen a 3.9% increase in shares over the past month [5] - DaVita HealthCare reported revenues of $3.29 billion for the last quarter, reflecting a year-over-year increase of 4.7%, with EPS rising from $1.87 to $2.24 [5] - For the current quarter, DaVita HealthCare is projected to report earnings of $1.75 per share, indicating a decline of 26.5% from the previous year, with no changes in the Zacks Consensus Estimate over the last 30 days [6]